Cellectis S.A. (NASDAQ:CLLS) Receives Consensus Rating of “Moderate Buy” from Analysts

Cellectis S.A. (NASDAQ:CLLS) has received a consensus recommendation of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $6.75.

A number of equities analysts have recently commented on CLLS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research note on Monday, April 20th. Citizens Jmp restated a “market outperform” rating and set a $8.00 price objective on shares of Cellectis in a research note on Tuesday, April 14th. Finally, Jefferies Financial Group started coverage on shares of Cellectis in a research note on Tuesday, February 17th. They set a “buy” rating and a $7.00 price objective for the company.

Hedge Funds Weigh In On Cellectis

A number of large investors have recently modified their holdings of CLLS. Global Retirement Partners LLC acquired a new stake in Cellectis in the 4th quarter valued at about $34,000. Millennium Management LLC lifted its stake in Cellectis by 61.9% in the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 22,080 shares during the last quarter. Delaney Dennis R acquired a new stake in Cellectis in the 3rd quarter valued at about $68,000. B Group Inc. lifted its stake in Cellectis by 0.8% in the 3rd quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock valued at $9,352,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in Cellectis in the 3rd quarter valued at about $72,000. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Price Performance

Shares of NASDAQ CLLS opened at $3.85 on Friday. The firm has a market cap of $386.31 million, a PE ratio of -5.75 and a beta of 2.94. The company has a current ratio of 1.62, a quick ratio of 1.62 and a debt-to-equity ratio of 0.98. Cellectis has a 1-year low of $1.33 and a 1-year high of $5.48. The company has a fifty day moving average price of $3.68 and a 200 day moving average price of $4.00.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Thursday, March 19th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Cellectis had a negative return on equity of 69.38% and a negative net margin of 84.92%.The business had revenue of $15.50 million for the quarter, compared to analyst estimates of $10.74 million.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.